title: Pharmaceuticals companies' medication assistance programs: potentially useful but too burdensome to use?
abstract: OBJECTIVE
  This study examined how physicians perceive pharmaceutical companies' medication assistance programs (MAPs).
  
  
  METHODS
  The study was conducted using a survey of 373 primary care physicians from four southern states; they were surveyed within the formative evaluation phase of a larger study (MI-Plus). Respondents were queried about use and usefulness of MAPs for patients who cannot afford drugs, and barriers to using them. Bivariate associations between physician-level variables (patients without drug coverage) and usefulness and barriers to using MAPs were assessed using Chi square tests. Independence of associations was assessed using multiple logistic regressions.
  
  
  RESULTS
  Of the 364 (97.6%) respondents who used MAPs, 70% used them regularly, the rest occasionally; 63% found MAPs very useful in caring for patients who could not afford drugs. About 89% reported one or more barriers to using MAPs; 47% saw "inability of patients to apply directly;" and 57% saw "enrollment process being time-consuming for staff" as barriers. Compared to physicians with fewer elderly patients without drug coverage, those with more of these patients were less likely to find MAPs very useful; less likely to report no barriers to using MAPs; and more likely to see "low income thresholds" and "inability of patients to apply directly" as barriers.
  
  
  CONCLUSIONS
  While MAPs are considered useful in caring for patients in need of assistance, there are many barriers to their use. Pharmaceutical companies should address these barriers. Limitations include a low response rate (about 10%).
authors.affiliation: Center for Outcomes and Effectiveness Research and Education and Division of Preventive Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Pisu
authors.forename: Joshua
authors.initials: J
authors.lastname: Richman
authors.forename: Jeroan J
authors.initials: JJ
authors.lastname: Allison
authors.forename: O Dale
authors.initials: OD
authors.lastname: Williams
authors.forename: Catarina I
authors.initials: CI
authors.lastname: Kiefe
mesh_terms: D016009:Chi-Square Distribution; D003258:Consumer Behavior; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D016015:Logistic Models; D008483:Medical Assistance; D017057:Medically Uninsured / Q000706:statistics & numerical data; D009203:Myocardial Infarction / Q000188:drug therapy; D004364:Pharmaceutical Preparations / Q000191:economics*; D010820:Physicians; D011795:Surveys and Questionnaires; D014481:United States
chemical_list: D004364:Pharmaceutical Preparations